Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
The latest drug development news and highlights from our FDA Performance Tracker
You may also be interested in...
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
The latest drug development news and highlights from our US FDA Performance Tracker.
A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.
The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.